Selected article for: "chloroquine phosphate and effective treatment"
Author: Iwasaka, Sho; Shono, Yuji; Tokuda, Kentaro; Nakashima, Kosuke; Yamamoto, Yuzo; Maki, Jun; Nagasaki, Yoji; Shimono, Nobuyuki; Akahoshi, Tomohiko; Taguchi, Tomoaki
Title: Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate
  • Cord-id: u8jgzhp1
  • Document date: 2020_8_6
    • ID: u8jgzhp1
    Snippet: Abstract The number of people infected with severe acute respiratory syndrome coronavirus 2 is increasing globally, and some patients have a fatal clinical course. In light of this situation, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic on March 11, 2020. While clinical studies and basic research on a treatment for COVID-19 are ongoing around the world, no treatment has yet been proven to be effective. Several clinical studies have demonstrated the
    Document: Abstract The number of people infected with severe acute respiratory syndrome coronavirus 2 is increasing globally, and some patients have a fatal clinical course. In light of this situation, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic on March 11, 2020. While clinical studies and basic research on a treatment for COVID-19 are ongoing around the world, no treatment has yet been proven to be effective. Several clinical studies have demonstrated the efficacy of chloroquine phosphate and nafamostat mesylate with COVID-19. Here, we report the case of a Japanese patient with COVID-19 with severe respiratory failure who improved following the administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate. Hence, hydroxychloroquine with nafamostat mesylate might be a treatment option for severe COVID-19.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and lung protective: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung protective ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung protective ventilation strategy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7
    • lung pneumonia and lupus erythematosus: 1
    • lung protective and lupus erythematosus: 1